Lirong Chen

Ms. Lirong Chen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Separation and Purification Technology
Verified
Journal Article
Closed access
YLYongjing Liu
Yongjing Liu
DHDongting Huang
Dongting Huang
LCLirong Chen
Lirong Chen
HYHuixin You
Huixin You
HLHua Li
Hua Li
WXWei Xu
Wei Xu

3 May 2025 in Molecules
Verified
Journal Article
Open access
PDF file
LCLirong Chen
Lirong Chen
TYTang Yan
Tang Yan
DHDongting Huang
Dongting Huang
WXWei Xu
Wei Xu
YLYongjing Liu
Yongjing Liu
HLHua Li
Hua Li
Farrerol, a bioactive compound found in Folium Rhododendri daurici, demonstrates various biological and pharmacological effects. Nevertheless, the stereoselectivity of in vivo processes and bioactivity between its enantiomers have not been thoroughly investigated. This study aimed to explore the stereoselectivity and pharmacological activity variations in farrerol enantiomers, focusing on stereoselective pharmacokinetics, tissue distribution, in vitro metabolism using liver microsomes, in vivo intestinal absorption, molecular simulations of binding affinity with antiproliferative target, and cell viability assessed through the CCK-8 assay. The findings indicated that the pharmacokinetic characteristics of farrerol in rats’ plasma, liver, and kidney tissues displayed enantioselectivity after intragastric administration. Then, no chiral transformation between farrerol enantiomers was observed in the rat plasma when (+)-farrerol and (−)-farrerol were orally administered. Additionally, there are notable stereoselective differences in the inhibition of CYP 1A2, CYP 2C9, CYP 2C19, and CYP 3A4/5 enzymes by (+)-farrerol and (−)-farrerol (p < 0.01). These differences may contribute to the stereoselectivity observed in the hepatic metabolism of the two enantiomers of farrerol. In addition, there were selective differences in the binding of farrerol enantiomers to anti-proliferative targets, including UCHL3, STAT3β, PTP1B, and GSK3β. Farrerol enantiomers exhibited similar growth inhibitory effects in HT-29 cell. Overall, our work will provide a solid theoretical basis and experimental reference for the further development and utilization of farrerol enantiomers.

20 November 2025 in Chirality
Verified
Journal Article
Closed access
LCLirong Chen
Lirong Chen
XCXiaofen Chen
Xiaofen Chen
DHDongting Huang
Dongting Huang
YLYongjing Liu
Yongjing Liu
YZYuqin Zhang
Yuqin Zhang
HLHua Li
Hua Li